ClearOne files draft information statement for Cortigent merger share issuancePUBT·Jul 17 at 04:24 PMCLRO-3.61%CRGT
Vivani Medical director, 10% owner Gregg Williams reports purchase of USD 999,999 common sharesPUBT·Jul 16 at 08:00 AMVANI-7.91%
Vivani Medical says first SLIM-1 dosing expected in August 2026 after CEO presentationTradingView·Jul 16 at 07:33 AMVANI-7.91%
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk DealMarket Beat·Jul 15 at 06:02 PMVANI-7.91%NVO+1.22%
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026Unusual Whales·Jul 14 at 03:04 PMVANI-7.91%
Novo Nordisk signs agreement with Vivani to evaluate semaglutide implant NPM-139CoinLive·Jul 11 at 07:02 AMVANI-7.91%NVO+1.22%
A tiny GLP-1 implant is the latest bet to help patients maintain their weight lossCNBC·Jul 11 at 07:00 AMVANI-7.91%NVO+1.22%
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goalrttnews·Jul 10 at 11:15 AMABBV+0.95%VANI-7.91%
Vivani Medical: Buy Rating Reaffirmed as Novo Nordisk Evaluation and Cortigent–ClearOne Merger Support $3.50 Price TargetTip Ranks·Jul 9 at 11:25 AMCRGTNVO+1.22%
Vivani Medical signs deal with Novo Nordisk to evaluate NPM-139 semaglutide implantPUBT·Jul 7 at 10:12 PMVANI-7.91%NVO+1.22%
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management | VANI Stock NewsStockTitan·Jul 6 at 10:35 PMVANI-7.91%NVO+1.22%
